Results for tag: "Non Proliferative Diabetic Retinopathy"

Non-proliferative diabetic retinopathy (NPDR) is the early stage of diabetic retinopathy, a complication of diabetes that affects the eyes. Within the context of optical health and market, NPDR treatment and management rely heavily on early detection and monitoring to prevent progression to more severe forms of retinopathy. Optical coherence tomography (OCT) and fundus photography are key imaging techniques used to diagnose and evaluate the extent of retinal damage. Manufacturers of such optical equipment, as well as companies developing pharmacological treatments aimed at controlling blood sugar levels and improving retinal health, constitute the NPDR market. The optical sector in NPDR also extends to include services offered by optometrists and ophthalmologists who play a crucial role in patient screening and treatment. Within the market, several companies are noted for their contributions to managing and treating NPDR. Names such as Novartis, Regeneron, and Roche are recognized for their work in pharmacotherapy, offering medications aimed at improving retinal health in diabetic patients. In terms of diagnostic imaging, companies such as Carl Zeiss Meditec, Topcon, and Canon provide advanced OCT and fundus cameras that are crucial for early detection and ongoing management of NPDR. These companies, among others, collaborate with healthcare providers to ensure patients receive comprehensive care to manage their condition and maintain optical health. Show Less Read more